B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Anixa Biosciences (ANIX) yesterday and set a price target of $9.00. The company’s shares closed last Thursday at $1.99.
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 12.4% and a 46.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals, EyePoint Pharmaceuticals, and Eton Pharmaceuticals.
Anixa Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.
See today’s analyst top recommended stocks >>
Based on Anixa Biosciences’ latest earnings release for the quarter ending April 30, the company reported a quarterly GAAP net loss of $2.64 million. In comparison, last year the company had a GAAP net loss of $2.14 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANIX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
